HIV-VAC Restructures and Acquires "Richard y Lange," a Mexican
Corporation

TORONTO, Aug 25, 2010 (MARKETWIRE via COMTEX) -- HIV-VAC, Inc.
(PINKSHEETS: HIVV) Kevin Murray, its President, announced today that
HIV-VAC has entered into a definitive agreement to acquire 80% of the
outstanding voting common stock of "Richard y Lange S.A. De C.V.," a
Mexican corporation for the consideration of the issuance of 8,000,000
HIV-VAC common shares.

In conjunction with the acquisition, holders of all of the currently
outstanding (10,000) Preferred Series "A" shares of HIV-VAC have agreed
to return their super voting Preferred Series "A" stock to treasury.
Mr. Murray stated, "We are very excited about this new acquisition in
that by diversifying our business model, we can now see immediate and
future growth for HIV-VAC."

Mr. Murray further stated that, over the past several years, HIV-VAC
has spent over $7,000,000 for the development of the HIV- Vaccine.
Additional funding will be necessary for the development of a
commercial vaccine which may be difficult in this present investment
climate. Management has decided that the best way to increase
shareholders value would be to diversify into new additional growth
opportunities. With the addition of the Richard y Lange operations,
management believes HIV-VAC can achieve excellent growth in a very
short time period.  It is expected that this growth will allow HIV-VAC
to continue its development and expansion to maximize shareholder
value.

In conjunction with the acquisition, HIV-VAC operations will be
separated into two distinct divisions. This will allow for the
continued development of vaccines in one division while, at the same
time, create an additional division that will allow for the expansion
of the international business of the newly acquired Richard y Lange
operations.

The Richard y Lange division will continue to operate under the names
of "RiMart," which presently operates 14 tool retail stores throughout
Baja California, "GR Construction," specializing in large industrial
projects, "Block GRYLSA," which operates block manufacturing
facilities, and "GRYLSA's," a raw materials division that mines
commercial grade sand located near the border of the State of
California and Baja California.

Management will operate each division separately while reporting
directly to the President, CEO and the Board of Directors of HIV-VAC.
Mr. Murray stated that HIV-VAC's name will be changed to Grupo
International, Inc. to better reflect its new direction,
diversification, and international business ventures. Mr. Ramon Richard
Mora, current CEO of Richard y Lange, will assume the duties of
president, CEO and director of Grupo International and a yet to be
named additional director will be appointed in the coming weeks. Mrs.
Sally del Principe has resigned as a director due to other commitments
and Ramon Richard Mora will replace her as a Director.

For additional information please contact Investors Relations listed
below:

2

Safe Harbor:
The information contained in this press release, including any
"forward-looking" statements within the meaning of section 27A of the
securities Act of 1993 and Section 21E of the Securities Exchange Act
of 1934 contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-KSB and other publicly available
information regarding the Company, copies of which are available from
the Company upon request. Such publicly available information sets
forth many risks and uncertainties related to the Company's business
and such statements, including risks and uncertainties related to that
are unpredictable and outside of the influence and/or control of the
Company. In particular, these risks and uncertainties include, without
limitation: that third parties may be successful in challenging the
patent issued; that granted claims may be held invalid or interpreted
differently by a court of law; that other patents will issue that will
block the Company from commercializing the technology covered by the
patents; and that the benefits that Company believes can be derived
from the patented technology will not be realized due to difficulties
encountered in the long and expensive process of the development of new
technologies and the cost and uncertainty in obtaining regulatory
approval for products based on these technologies. In addition, there
are many other risks and uncertainties inherent in the development of
the Company's products, including the risk of not obtaining regulatory
approval for a variety of reasons and the risk of adverse side effects
in humans. Other risks relating to Company are detailed from time to
time in documents filed by Company with the SEC.

CONTACT:
HIV-VAC, Inc.
Kevin W. Murray, CEO
Unit 1, 2700 Nottawa Conc 6
Collingwood, Ontario, Canada L9Y 5A8
Tel: (705) 446-7242

Investor Relations:
Email: Investorrelations@grupointl.com
(702) 952-3998


SOURCE: HIV-VAC, Inc.
mailto:Investorrelations@grupointl.com